Last reviewed · How we verify

NCT02263638: THERA

Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study

Terminated Phase 2 Last updated 12 March 2019
What this trial tests

Phase 2 trial testing Anakinra in Refractory Hemochromatosis Rheumatism in 17 participants. Terminated before completion.

Timeline
4 February 2015
Primary endpoint
4 September 2018
4 September 2018

Quick facts

Lead sponsorRennes University Hospital
PhasePhase 2
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment17
Start date4 February 2015
Primary completion4 September 2018
Estimated completion4 September 2018
Sites3 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Rennes University Hospital

Who can join

18 and older, any sex, with Refractory Hemochromatosis Rheumatism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment of refractory hemochromatosis rheumatism by Anakinra. Prospective, multicenter, non-randomised, single-arm, open-label, phase II trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Anakinra

Trials testing the same drug.

Other Rennes University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02263638.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing